EGFR blocker lapatinib inhibits the synthesis of matrix metalloproteinases from synovial fibroblasts
Yıl: 2022 Cilt: 52 Sayı: 4 Sayfa Aralığı: 1355 - 1361 Metin Dili: İngilizce DOI: 10.55730/1300-0144.5442 İndeks Tarihi: 26-12-2022
EGFR blocker lapatinib inhibits the synthesis of matrix metalloproteinases from synovial fibroblasts
Öz: Background/aim: Epidermal growth factor receptor (EGFR) family members and their associated ligands may be related to bone and joint destruction in rheumatoid arthritis. Matrix metalloproteinases are responsible for joint and bone tissue degradation. This study is intended to investigate the effect of epidermal growth factor receptor inhibition by lapatinib on the synthesis of matrix metalloproteinases in in vitro. Materials and methods: Synovial fibroblast cell culture was obtained from a patient with rheumatoid arthritis who underwent knee arthroplasty. Interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α) were added to the cell culture to stimulate synovial fibroblast cells and create an inflammatory character. Understimulated and nonstimulated conditions, lapatinib was applied to the culture in four different concentrations of 25, 50, 100, and 200 μmol. Then, matrix metalloproteinase -1, -3, and, -13 levels were assessed. Results: When stimulated with IL-1β and TNF-α, the synthesis of matrix metalloproteinases from synovial fibroblast was increased significantly. When lapatinib is added to the stimulated synovial fibroblasts, matrix metalloproteinases synthesis is significantly suppressed. Conclusion: Inhibition of the EGFR pathway with lapatinib suppresses matrix metalloproteinases synthesis. Our results suggest EGFR pathway inhibition may be a promising option to prevent joint destruction in the treatment of rheumatoid arthritis.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- 1. Pap T, Distler O. Linking Angiogenesis to Bone Destruction in Arthritis. Arthritis & Rheumatism 2005; 52 (5): 1346-1348. doi: 10.1002/art.21015
- 2. Clavel G, Bessis N, Boissier MC. Recent data on the role of angiogenesis in rheumatoid arthritis. Joint Bone Spine 2003; 70 (5): 321-326. doi: 10.1016/s1297-319x(03)00088-5
- 3. Nagashima M, Tanaka H, Takahashi H, Tachihara A, Tanaka K et al. Study of the mechanism involved in angiogenesis and synovial cell proliferation in human synovial of patients with rheumatoid arthritis using SCID mice. Laboratory Investigation 2002; 82 (8): 981-988. doi: 10.1097/01. lab.0000022220.44511.40
- 4. Burrage PS, Mix KS, Brinckerhoff CE. Matrix metalloproteinases: role in arthritis. Frontiers in Bioscience 2006; 11: 529-543. doi: 10.2741/1817
- 5. Kusada J, Otsuka T, Matsui N, Hirano T, Asai K et al. T. Immuno-reactive human epidermal growth factor (h-EGF) in rheumatoid synovial fluids. Nippon Seikeigeka Gakkai Zasshi 1993; 67 (9): 859-865
- 6. Zhang Z, Song T, Jin Y, Pan J, Zhang L et al. Epidermal growth factor receptor regulates MT1-MMP and MMP-2 synthesis in SiHa cells via both PI3-K/AKT and MAPK/ERK pathways. International Journal of Gynecological Cancer 2009; 19 (6): 998-1003. doi: 10.1111/IGC.0b013e3181a83749
- 7. Kim HP, Yoon YK, Kim JW, Han SW, Hur HS et al. Lapatinib, a dual EGFR, and HER2 tyrosine kinase inhibitor, downregulates thymidylate synthase by inhibiting the nuclear translocation of EGFR and HER2. PLoS One 2009; 16 (6): 5933. doi: 10.1371/ journal.pone.0005933
- 8. Vingsbo C, Sahlstrand P, Brun JG, Jonsson R, Saxne T et al. R. Pristan-induced arthritis in rats: a new model for rheumatoid arthritis with a chronic disease course influenced by both major histocompatibility complex and non-major histocompatibility complex genes. The American Journal of Pathology 1996; 149 (5): 1675-1683
- 9. Hoffmann M, Hayer S, Steiner G. Immunopathogenesis of rheumatoid arthritis; induction of arthritogenic autoimmune responses by proinflammatory stimuli. Annals of the New York Academy of Sciences 2009; 1173: 391-400. doi: 10.1111/j.1749- 6632.2009.04753.x
- 10. Lo SF, Wan L, Lin HC, Huang CM, Chen SY et al. Association of rheumatoid arthritis risk with EGFR genetic polymorphisms in Taiwan’s Han Chinese population. Rheumatology International 2012; 32 (8): 2301-2306. doi: 10.1007/s00296-011-1961-4
- 11. Perrotte P, Matsumoto T, Inoue K, Kuniyasu H, Eve BY et al. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clinical Cancer Research 1999; 5 (2): 257-265
- 12. Goldman CK, Kim J, Wong WL, Brock T, Gillespie GY. Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology. Molecular Biology of the Cell 1993; 4 (1): 121-133. doi: 10.1091/mbc.4.1.121
- 13. Inoue T, Kohno M, Nagahara H, Murakami K, Sagawa T et al. Upregulation of sphingosine-1-phosphate receptor 3 on fibroblast-like synoviocytes is associated with the development of collagen-induced arthritis via increased interleukin-6 production. PLoS One 2019; 14 (6): e0218090. doi: 0.1371/ journal.pone.0218090
- 14. Özdemir Z, Türkmen NB, Ayhan İ, Çiftçi O, Uysal M. Synthesis of New 6-(4-(2- Fluorophenylpiperazine-1-YL))-3(2H)- Pyridazinone-2-Acethyl-2 (Substitutedbenzal) Hydrazone Derivatives and Evaluation of Their Cytotoxic Effects in Liver and Colon Cancer Cell Lines. Pharmaceutical Chemistry Journal 2019; 52: 923. doi: 10.1007/s11094-019-01927-y
- 15. Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nature Reviews Cancer 2007; 7 (3): 169-181. doi: 10.1038/nrc2088
- 16. Huber LC, Künzler P, Boyce SH, Michel BA, Gay RE et al. Effects of a novel tyrosine kinase inhibitor in rheumatoid arthritis synovial fibroblasts. Annals of Rheumatic Disease 2008; 67 (3): 389-394. doi: 10.1136/ard.2007.072330
- 17. Albitar L, Pickett G, Morgan M, Wilken JA, Maihle NJ et al. EGFR isoforms and gene regulation in human endometrial cancer cells. Molecular Cancer 2010; 9: 166. doi: 10.1186/1476- 4598-9-166
- 18. Müller-Ladner U, Ospelt C, Gay S, Distler O, Pap T. Cells of the synovium in rheumatoid arthritis. Synovial fibroblasts. Arthritis Research & Therapy 2007; 9 (6): 223. doi: 10.1186/ar2337
- 19. Silverman GJ, Carson DA. Roles of B cells in rheumatoid arthritis. Arthritis Research & Therapy 2003; 5 (4): 1-6. doi: 10.1186/ar1010
- 20. Yuan FL, Li X, Lu WG, Sun JM, Jiang D et al. Epidermal growth factor receptor (EGFR) as a therapeutic target in rheumatoid arthritis. Clinical Rheumatology 2013; 32 (3): 289-292. doi: 10.1007/s10067-012-2119-9
- 21. Swanson CD, Akama-Garren EH, Stein EA, Petralia JD, Ruiz PJ et al. Inhibition of epidermal growth factor receptor tyrosine kinase ameliorates collagen-induced arthritis. The Journal of Immunology 2012; 188 (7): 3513-3521. doi: 10.4049/ jimmunol.1102693
- 22. Itoh Y. Metalloproteinases in Rheumatoid Arthritis: Potential Therapeutic Targets to Improve Current Therapies. Progress in Molecular Biology and Translational Science 2017; 148: 327- 338. doi: 10.1016/bs.pmbts.2017.03.002
- 23. Murphy G, Nagase H. Reappraising metalloproteinases in rheumatoid arthritis and osteoarthritis: destruction or repair? Nature Clinical Practice Rheumatology 2008; 4 (3): 128-135. doi: 10.1038/ncprheum0727
- 24. Yu Q, Stamenkovic I. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-b and promotes tumor invasion and angiogenesis. Genes & Development 2000; 14 (2): 163-176
- 25. Jabłońska-Trypuć A, Matejczyk M, Rosochacki S. Matrix metalloproteinases (MMPs), the main extracellular matrix (ECM) enzymes in collagen degradation, as a target for anticancer drugs. Journal of Enzyme Inhibition and Medicinal Chemistry 2016; 31 (1): 177-183. doi: 10.3109/14756366.2016.1161620
- 26. Gifford V, Itoh Y. MT1-MMP-dependent cell migration: proteolytic and non-proteolytic mechanisms. Biochemical Society Transactions 2019; 47 (3): 811-826. doi: 10.1042/ BST20180363
- 27. Wang X, Khalil RA. Matrix metalloproteinases, vascular remodeling, and vascular disease. Advances in Pharmacology 2018; 81: 241-330. doi: 10.1016/bs.apha.2017.08.002
| APA | Yalcin Kehribar D, emmungil h, başak türkmen n, ÇİFTÇİ O, Salva E, Ozgen M (2022). EGFR blocker lapatinib inhibits the synthesis of matrix metalloproteinases from synovial fibroblasts. , 1355 - 1361. 10.55730/1300-0144.5442 |
| Chicago | Yalcin Kehribar Demet,emmungil hakan,başak türkmen neşe,ÇİFTÇİ OSMAN,Salva Emine,Ozgen Metin EGFR blocker lapatinib inhibits the synthesis of matrix metalloproteinases from synovial fibroblasts. (2022): 1355 - 1361. 10.55730/1300-0144.5442 |
| MLA | Yalcin Kehribar Demet,emmungil hakan,başak türkmen neşe,ÇİFTÇİ OSMAN,Salva Emine,Ozgen Metin EGFR blocker lapatinib inhibits the synthesis of matrix metalloproteinases from synovial fibroblasts. , 2022, ss.1355 - 1361. 10.55730/1300-0144.5442 |
| AMA | Yalcin Kehribar D,emmungil h,başak türkmen n,ÇİFTÇİ O,Salva E,Ozgen M EGFR blocker lapatinib inhibits the synthesis of matrix metalloproteinases from synovial fibroblasts. . 2022; 1355 - 1361. 10.55730/1300-0144.5442 |
| Vancouver | Yalcin Kehribar D,emmungil h,başak türkmen n,ÇİFTÇİ O,Salva E,Ozgen M EGFR blocker lapatinib inhibits the synthesis of matrix metalloproteinases from synovial fibroblasts. . 2022; 1355 - 1361. 10.55730/1300-0144.5442 |
| IEEE | Yalcin Kehribar D,emmungil h,başak türkmen n,ÇİFTÇİ O,Salva E,Ozgen M "EGFR blocker lapatinib inhibits the synthesis of matrix metalloproteinases from synovial fibroblasts." , ss.1355 - 1361, 2022. 10.55730/1300-0144.5442 |
| ISNAD | Yalcin Kehribar, Demet vd. "EGFR blocker lapatinib inhibits the synthesis of matrix metalloproteinases from synovial fibroblasts". (2022), 1355-1361. https://doi.org/10.55730/1300-0144.5442 |
| APA | Yalcin Kehribar D, emmungil h, başak türkmen n, ÇİFTÇİ O, Salva E, Ozgen M (2022). EGFR blocker lapatinib inhibits the synthesis of matrix metalloproteinases from synovial fibroblasts. Turkish Journal of Medical Sciences, 52(4), 1355 - 1361. 10.55730/1300-0144.5442 |
| Chicago | Yalcin Kehribar Demet,emmungil hakan,başak türkmen neşe,ÇİFTÇİ OSMAN,Salva Emine,Ozgen Metin EGFR blocker lapatinib inhibits the synthesis of matrix metalloproteinases from synovial fibroblasts. Turkish Journal of Medical Sciences 52, no.4 (2022): 1355 - 1361. 10.55730/1300-0144.5442 |
| MLA | Yalcin Kehribar Demet,emmungil hakan,başak türkmen neşe,ÇİFTÇİ OSMAN,Salva Emine,Ozgen Metin EGFR blocker lapatinib inhibits the synthesis of matrix metalloproteinases from synovial fibroblasts. Turkish Journal of Medical Sciences, vol.52, no.4, 2022, ss.1355 - 1361. 10.55730/1300-0144.5442 |
| AMA | Yalcin Kehribar D,emmungil h,başak türkmen n,ÇİFTÇİ O,Salva E,Ozgen M EGFR blocker lapatinib inhibits the synthesis of matrix metalloproteinases from synovial fibroblasts. Turkish Journal of Medical Sciences. 2022; 52(4): 1355 - 1361. 10.55730/1300-0144.5442 |
| Vancouver | Yalcin Kehribar D,emmungil h,başak türkmen n,ÇİFTÇİ O,Salva E,Ozgen M EGFR blocker lapatinib inhibits the synthesis of matrix metalloproteinases from synovial fibroblasts. Turkish Journal of Medical Sciences. 2022; 52(4): 1355 - 1361. 10.55730/1300-0144.5442 |
| IEEE | Yalcin Kehribar D,emmungil h,başak türkmen n,ÇİFTÇİ O,Salva E,Ozgen M "EGFR blocker lapatinib inhibits the synthesis of matrix metalloproteinases from synovial fibroblasts." Turkish Journal of Medical Sciences, 52, ss.1355 - 1361, 2022. 10.55730/1300-0144.5442 |
| ISNAD | Yalcin Kehribar, Demet vd. "EGFR blocker lapatinib inhibits the synthesis of matrix metalloproteinases from synovial fibroblasts". Turkish Journal of Medical Sciences 52/4 (2022), 1355-1361. https://doi.org/10.55730/1300-0144.5442 |
